Bupivacaine liposome is one of 39 small molecule programs targeting Cognitive Disorder. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
23 competitors in Postoperative Analgesia
Precedex
Decadron
Duragesic
Nubain
Celebrex
EXPAREL
Intrathecal Morphine
Bupivacaine Only
Bupivacaine liposome
Anrikefon
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details